Retraction:Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on tyrosine hydroxylase and α-synuclein in human neuroblastoma SH-SY5Y cells(Journal of Neurochemistry, (2008), 107, (6), (1722–1729), 10.1111/j.1471-4159.2008.05736.x);Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on tyrosine hydroxylase and α-synuclein in human neuroblastoma SH-SY5Y cells

Journal of Neurochemistry

Volumn 107, Issue 6, 2008, Pages 1722-1729

  Rantham Prabhakara, Jaya Prasanthi ^a   Feist, Gwen ^a   Thomasson, Sarah ^a   Thompson, Alex ^a   Schommer, Eric ^a   Ghribi, Othman ^a  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

24 hydroxycholesterol; 27 hydroxycholesterol; Apoptosis; Oxysterols; Tyrosine hydroxylase; synuclein

Indexed keywords

24 HYDROXYCHOLESTEROL; 26 HYDROXYCHOLESTEROL; ALPHA SYNUCLEIN; CHOLESTEROL; CHOLESTEROL DERIVATIVE; DOPAMINE; LACTATE DEHYDROGENASE; NORADRENALIN; OXYSTEROL; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BRAIN TISSUE; CELL DIFFERENTIATION; CELL VIABILITY; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DOPAMINE METABOLISM; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEADY STATE; TISSUE LEVEL;

EID: 56749183934     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.15832     Document Type: Erratum

References (22)

1. Alerte T. N., Akinfolarin A. A., Friedrich E. E., Mader S. A., Hong C. S. Perez R. G. (2008) Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice. Neurosci. Lett. 11, 24 29.
2. 2+ channel blockers verapamil and nifedipine inhibit apoptosis induced by 25-hydroxycholesterol in human aortic smooth muscle cells. J. Lipid Res. 38, 2049 2061.
3. Bjorkhem I. Meaney S. (2004) Brain cholesterol: long secret life behind a barrier. Arterioscler. Thromb. Vasc. Biol. 24, 806 815.
4. Bjorkhem I., Lutjohann D., Breuer O., Sakinis A. Wennmalm A. (1997) Importance of a novel oxidative mechanism for elimination of brain cholesterol. Turnover of cholesterol and 24(S)-hydroxycholesterol in rat brain as measured with 18O2 techniques in vivo and in vitro. J. Biol. Chem. 272, 30178 30184.
5. Bjorkhem I., Meaney S. Diczfalusy U. (2002) Oxysterols in human circulation: which role do they have? Curr. Opin. Lipidol. 13, 247 253.
6. Björkhem I., Heverin M., Leoni V., Meaney S. Diczfalusy U. (2006) Oxysterols and Alzheimer's disease. Acta Neurol. Scand. 185, 43 49.
7. Bosco D. A., Fowler D. M., Zhang Q., Nieva J., Powers E. T., Wentworth P., Lerner R. A. Kelly J. W. (2006) Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. Nat. Chem. Biol. 2, 249 253.
8. De Lau L. M., Bornebroek M., Witteman J. C., Hofman A., Koudstaal P. J. Breteler M. M. (2005) Dietary fatty acids and the risk of Parkinson disease: the Rotterdam study. Neurology 64, 2040 2045.
9. Fotakis G. Timbrell J. A. (2006) In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicol. Lett. 160, 171 177.
10. Heverin M., Meaney S., Lutjohann D., Diczfalusy U., Wahren J. Bjorkhem I. (2005) Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. J. Lipid Res. 46, 1047 1052.
11. Hu G., Antikainen R., Jousilahti P., Kivipelto M. Tuomilehto J. (2008) Total cholesterol and the risk of Parkinson disease. Neurology 70, 1972 1979.
12. Johnson C. C., Gorell J. M., Rybicki B. A., Sanders K. Peterson E. L. (1999) Adult nutrient intake as a risk factor for Parkinson's disease. Int. J. Epidemiol. 28, 1102 1109.
13. Kolsch H., Lutjohann D., Tulke A., Bjorkhem I. Rao M. L. (1999) The neurotoxic effect of 24-hydroxycholesterol on SH-SY5Y human neuroblastoma cells. Brain Res. 818, 171 175.
14. Kolsch H., Ludwig M., Lutjohann D. Rao M. L. (2001) Neurotoxicity of 24-hydroxycholesterol, an important cholesterol elimination product of the brain, may be prevented by vitamin E and estradiol-17beta. J. Neural Transm. 108, 475 488.
15. Kumer S. C. Vrana K. E. (1996) Intricate regulation of tyrosine hydroxylase activity and gene expression. J. Neurochem. 67, 443 462.
16. Langston J. W. (1998) Epidemiology versus genetics in Parkinson's disease: progress in resolving an age-old debate. Ann. Neurol. 44, 45 52.
17. Lindley J. W., Jung A. E., Narayanan T. K. Ritchie G. D. (1998) Acute effects of a bicyclophosphate neuroconvulsant on monoamine neurotransmitter and metabolite levels in the rat brain. J. Toxicol. Envir. Health. 54, 421 429.
18. Lutjohann D., Breuer O., Ahlborg G., Nennesmo I., Siden A., Diczfalusy U. Bjorkhem I. (1996) Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc. Natl Acad. Sci. USA 93, 9799 9804.
19. Ohtani K., Miyabara K., Okamoto E., Kamei M. Matsui-Yuasa I. (1996) Cytotoxicity of 7-ketocholesterol toward cultured rat hepatocytes and the effect of vitamin E. Biosci. Biotechnol. Biochem. 60, 1989 1993.
20. Powers K. M., Smith-Weller T., Franklin G. M., Longstreth W. T. Jr., Swanson P. D. Checkoway H. (2008) Dietary fats, cholesterol and iron as risk factors for Parkinson's disease. Parkinsonism Relat. Disord. (In press) doi:.
21. Scigliano G., Musicco M., Soliveri P., Piccolo I., Ronchetti G. Girotti F. (2006) Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke 37, 1184 1188.
22. Xie C., Lund E. G., Turley S. D., Russell D. W. Dietschy J. M. (2003) Quantitation of two pathways for cholesterol excretion from the brain in normal mice and mice with neurodegeneration. J. Lipid Res. 44, 1780 1789.